{
    "root": "3133e596-4212-c9cd-e063-6294a90a06f2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Gabapentin",
    "value": "20250325",
    "ingredients": [
        {
            "name": "POLOXAMER 407",
            "code": "TUF2IVW3M2"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "GABAPENTIN",
            "code": "6CW7F3G59X"
        }
    ],
    "indications": "gabapentin indicated : management postherpetic neuralgia adults adjunctive therapy treatment partial onset seizures , without secondary generalization , adults pediatric patients 3 years older epilepsy",
    "contraindications": "postherpetic neuralgia ( 2.1 ) dose titrated needed dose 1800 mg/day day 1 : single 300 mg dose day 2 : 600 mg/day ( i.e . , 300 mg two times day ) day 3 : 900 mg/day ( i.e . , 300 mg three times day ) epilepsy partial onset seizures ( 2.2 ) patients 12 years age older : starting dose 300 mg three times daily ; may titrated 600 mg three times daily patients 3 11 years age : starting dose range 10 15 mg/kg/day , given three divided doses ; recommended dose patients 3 4 years age 40 mg/kg/day , given three divided doses ; recommended dose patients 5 11 years age 25 35 mg/kg/day , given three divided doses . recommended dose reached upward titration period approximately 3 days dose adjusted patients reduced renal function ( 2.3 , 2.4 )",
    "warningsAndPrecautions": "gabapentin capsules tablets , usp supplied follows : 100 mg capsules : white off-white powder filled size \u201c 3 \u201d hard gelatin capsules opaque white colored cap opaque white colored body imprinted sgon cap 179on body black ink , available : bottles 30 : ndc 50228-179-30 bottles 100 : ndc 50228-179-01 bottles 500 : ndc 50228-179-05 bottles 1000 : ndc 50228-180-10 bulk pack : ndc 50228-180-00 300 mg capsules : white off-white powder filled size \u201c 1 \u201d hard gelatin capsules opaque yellow colored cap opaque yellow colored body imprinted sgon cap 180on body black ink , available : bottles 30 : ndc 50228-180-30 bottles 100 : ndc 50228-180-01 bottles 500 : ndc 50228-180-05 bottles 1000 : ndc 50228-180-10 400 mg capsules : white off-white powder filled size \u201c 0 \u201d hard gelatin capsules opaque orange colored cap opaque orange colored body imprinted sgon cap 181on body black ink , available : bottles 30 : ndc 50228-181-30 bottles 100 : ndc 50228-181-01 bottles 500 : ndc 50228-181-05 600 mg tablets : white white , modified capsule shape , biconvex , film-coated functional scored tablets debossed \u201c sg \u201d one side \u201c 177 \u201d side bisect line sides , available : bottles 30 : ndc 50228-177-30 bottles 100 : ndc 50228-177-01 bottles 500 : ndc 50228-177-05 800 mg tablets : white white , modified capsule shape , biconvex , film-coated functional scored tablets debossed \u201c sg \u201d one side \u201c 178 \u201d side bisect line sides , available : bottles 30 : ndc 50228-178-30 bottles 100 : ndc 50228-178-01 bottles 500 : ndc 50228-178-05 store gabapentin capsules tablets 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "gabapentin contraindicated patients demonstrated hypersensitivity ingredients .",
    "indications_original": "Gabapentin is indicated for:\n                  \n                     Management of postherpetic neuralgia in adults\n                     Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy",
    "contraindications_original": "Postherpetic Neuralgia ( 2.1 ) o Dose can be titrated up as needed to a dose of 1800 mg/day o Day 1: Single 300 mg dose o Day 2: 600 mg/day (i.e., 300 mg two times a day) o Day 3: 900 mg/day (i.e., 300 mg three times a day) Epilepsy with Partial Onset Seizures ( 2.2 ) Patients 12 years of age and older: starting dose is 300 mg three times daily; may be titrated up to 600 mg three times daily Patients 3 to 11 years of age: starting dose range is 10 to 15 mg/kg/day, given in three divided doses; recommended dose in patients 3 to 4 years of age is 40 mg/kg/day, given in three divided doses; the recommended dose in patients 5 to 11 years of age is 25 to 35 mg/kg/day, given in three divided doses. The recommended dose is reached by upward titration over a period of approximately 3 days Dose should be adjusted in patients with reduced renal function ( 2.3 , 2.4 )",
    "warningsAndPrecautions_original": "Gabapentin capsules and tablets, USP are supplied as follows:\n                  100 mg capsules:\n                  White to off-white powder filled in size \u201c3\u201d hard gelatin capsules with opaque white colored cap and opaque white colored body imprinted\n \n  SGon cap and\n \n  179on body with black ink, available in:\n\n \n                  Bottles of 30: NDC 50228-179-30\n                  Bottles of 100: NDC 50228-179-01\n                  Bottles of 500: NDC 50228-179-05\n                  Bottles of 1000: NDC 50228-180-10\n                  Bulk pack: NDC 50228-180-00\n                  300 mg capsules:\n                  White to off-white powder filled in size \u201c1\u201d hard gelatin capsules with opaque yellow colored cap and opaque yellow colored body imprinted\n \n  SGon cap and\n \n  180on body with black ink, available in:\n\n \n                  Bottles of 30: NDC 50228-180-30\n                  Bottles of 100: NDC 50228-180-01\n                  Bottles of 500: NDC 50228-180-05\n                  Bottles of 1000: NDC 50228-180-10\n                  400 mg capsules:\n                  White to off-white powder filled in size \u201c0\u201d hard gelatin capsules with opaque orange colored cap and opaque orange colored body imprinted\n \n  SGon cap and\n \n  181on body with black ink, available in:\n\n \n                  Bottles of 30: NDC 50228-181-30\n                  Bottles of 100: NDC 50228-181-01\n                  Bottles of 500: NDC 50228-181-05\n                  600 mg tablets:\n                  White to off white, modified capsule shape, biconvex, film-coated functional scored tablets debossed with \u201cSG\u201d on one side and \u201c177\u201d on other side with bisect line on both sides, available in:\n                  Bottles of 30: NDC 50228-177-30\n                  Bottles of 100: NDC 50228-177-01\n                  Bottles of 500: NDC 50228-177-05\n                  800 mg tablets:\n                  White to off white, modified capsule shape, biconvex, film-coated functional scored tablets debossed with \u201cSG\u201d on one side and \u201c178\u201d on other side with bisect line on both sides, available in:\n                  Bottles of 30: NDC 50228-178-30\n                  Bottles of 100: NDC 50228-178-01\n                  Bottles of 500: NDC 50228-178-05\n                  Store gabapentin capsules and tablets at 25\u00b0C (77\u00b0F); excursions permitted between 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Gabapentin is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients."
}